AR117655A1 - Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal - Google Patents

Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal

Info

Publication number
AR117655A1
AR117655A1 ARP190102972A ARP190102972A AR117655A1 AR 117655 A1 AR117655 A1 AR 117655A1 AR P190102972 A ARP190102972 A AR P190102972A AR P190102972 A ARP190102972 A AR P190102972A AR 117655 A1 AR117655 A1 AR 117655A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
oral administration
aminopyrimidine
salt
derivative
Prior art date
Application number
ARP190102972A
Other languages
English (en)
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of AR117655A1 publication Critical patent/AR117655A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona una composición farmacéutica para administración oral que comprende: N-(5-(4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidina-2-ilamino)-4-metoxi-2-morfolinofenil)acrilamida (Lazertinib) o su sal farmacéuticamente aceptable como un ingrediente activo; y una combinación de celulosa microcristalina y manitol como un diluyente.
ARP190102972A 2018-10-18 2019-10-18 Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal AR117655A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180124171A KR20200043618A (ko) 2018-10-18 2018-10-18 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Publications (1)

Publication Number Publication Date
AR117655A1 true AR117655A1 (es) 2021-08-25

Family

ID=70282933

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102972A AR117655A1 (es) 2018-10-18 2019-10-18 Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal

Country Status (28)

Country Link
US (1) US20210322428A1 (es)
EP (2) EP3866767B1 (es)
JP (2) JP7369769B2 (es)
KR (2) KR20200043618A (es)
CN (1) CN113015521A (es)
AR (1) AR117655A1 (es)
AU (1) AU2019360446A1 (es)
BR (1) BR112021007061A2 (es)
CA (1) CA3116652A1 (es)
DK (1) DK3866767T3 (es)
EA (1) EA202191061A1 (es)
ES (1) ES2968966T3 (es)
FI (1) FI3866767T3 (es)
HR (1) HRP20231670T1 (es)
HU (1) HUE065389T2 (es)
IL (1) IL282163A (es)
LT (1) LT3866767T (es)
MA (1) MA53927B1 (es)
MX (1) MX2021004457A (es)
PE (1) PE20211818A1 (es)
PH (1) PH12021550687A1 (es)
PL (1) PL3866767T3 (es)
PT (1) PT3866767T (es)
RS (1) RS65012B1 (es)
SG (1) SG11202103057RA (es)
SI (1) SI3866767T1 (es)
TW (1) TWI831848B (es)
WO (1) WO2020079637A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CN117425651A (zh) 2021-06-01 2024-01-19 杭州领业医药科技有限公司 Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338256C (en) * 1998-07-20 2008-09-23 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
DE10319450A1 (de) 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
ES2359377T3 (es) * 2006-10-27 2011-05-23 Fmc Corporation Celulosa microcristalina coprocesada y alcohol de azúcar como excipiente para formulaciones de comprimidos.
US7998505B2 (en) 2006-10-27 2011-08-16 Fmc Corporation Dry granulation binders, products, and use thereof
US11453646B2 (en) * 2011-07-27 2022-09-27 Cornell University Methods for RNA detection and quantification
MX356105B (es) 2011-09-14 2018-05-14 Celgene Corp Formulaciones de ácido ciclopropancarboxílico de {2-[(1s)-1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-3-oxo-2 ,3-dihidro-1h-isoindol-4-il}-amida.
CN104039319B (zh) 2011-11-29 2017-12-29 吉利德制药有限责任公司 用于治疗hcv的组合物和方法
WO2014175986A2 (en) * 2013-04-23 2014-10-30 RevOrtho LLC A method and system for modular hip resurfacing
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR102487451B1 (ko) 2014-10-13 2023-01-11 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
JP6762940B2 (ja) 2014-12-16 2020-09-30 シグナル ファーマシューティカルズ，エルエルシー ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの製剤
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AU2016268477B2 (en) 2015-05-22 2018-12-20 Novartis Ag Pharmaceutical compositions
WO2017061621A1 (ja) 2015-10-07 2017-04-13 協和発酵キリン株式会社 アリールアルキルアミン化合物含有医薬組成物
PT3439653T (pt) * 2016-04-07 2021-03-25 Chemocentryx Inc Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物

Also Published As

Publication number Publication date
ES2968966T3 (es) 2024-05-14
EP3866767B1 (en) 2023-11-29
EP3866767A4 (en) 2022-07-20
RS65012B1 (sr) 2024-01-31
TW202034903A (zh) 2020-10-01
DK3866767T3 (da) 2024-01-29
SG11202103057RA (en) 2021-05-28
FI3866767T3 (fi) 2024-01-30
EP4306113A3 (en) 2024-02-14
JP7369769B2 (ja) 2023-10-26
CA3116652A1 (en) 2020-04-23
US20210322428A1 (en) 2021-10-21
JP2024016052A (ja) 2024-02-06
PL3866767T3 (pl) 2024-04-02
JP2022504943A (ja) 2022-01-13
PH12021550687A1 (en) 2022-02-14
CN113015521A (zh) 2021-06-22
PE20211818A1 (es) 2021-09-14
AU2019360446A1 (en) 2021-04-22
PT3866767T (pt) 2024-01-18
HUE065389T2 (hu) 2024-05-28
LT3866767T (lt) 2023-12-27
MA53927A (fr) 2021-09-15
EP4306113A2 (en) 2024-01-17
KR20200043618A (ko) 2020-04-28
MX2021004457A (es) 2021-07-07
MA53927B1 (fr) 2023-12-29
BR112021007061A2 (pt) 2021-07-20
TWI831848B (zh) 2024-02-11
EA202191061A1 (ru) 2021-07-09
SI3866767T1 (sl) 2024-02-29
IL282163A (en) 2021-05-31
KR20210061457A (ko) 2021-05-27
HRP20231670T1 (hr) 2024-03-15
EP3866767A1 (en) 2021-08-25
WO2020079637A9 (en) 2020-07-23
WO2020079637A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
AR117655A1 (es) Composición farmacéutica para administración oral que comprende derivado de aminopirimidina o su sal
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
AR085689A1 (es) Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
EA201190011A1 (ru) Пероральные лекарственные формы бендамустина
CL2017001479A1 (es) Combinación farmacéutica que comprende un agonista selectivo del receptor s1p1
BR112020007589A8 (pt) Derivados de benzimidazol e seus usos
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
RS54420B1 (en) FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT
CO6290762A2 (es) Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral
EA201001125A1 (ru) Фармацевтические композиции, включающие n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамид